Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has begun the patient recruitment process for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. The announcement marks a significant step in the company's clinical development program, as the study expands its focus from safety to include near and distance vision performance.
Unlike the first group, which concentrated solely on safety, Group Two is designed to evaluate the safety, distance, and near vision performance of the Ocumetics Lens. The Mexico City facility, which successfully conducted Group One surgeries in Fall 2025, is now identifying and recruiting eligible patients in preparation for surgeries scheduled for Fall 2026. According to Dean Burns, President and CEO of Ocumetics, the commencement of the Group Two study is a critical milestone. "We are extremely excited to begin the process of moving into our larger Group Two study," Burns said. "Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
Group Two patients will receive the latest-generation Ocumetics Lens, which incorporates the company's latest design advancements, and will be implanted using an enhanced delivery system. This combination represents the continued evolution of the technology, according to Burns. "We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens," he added. "At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system."
The Group One clinical outcomes met and exceeded the company's expectations regarding safety, performance, and handling, providing valuable insights for the next phase. Patients from Group One continue to be followed as part of the ongoing clinical evaluation, with 12-month follow-up visits now in progress. This data will contribute to the understanding of the lens's long-term effects.
Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions. The company is conducting first-in-human early feasibility studies for its dynamic intraocular lens, which is designed to fit within the natural lens compartment of the eye and potentially eliminate the need for corrective lenses. The lens aims to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without perceptible time lag.
The initiation of patient recruitment for Group Two is a pivotal development for the company, as it advances its clinical program and moves closer to potentially offering a transformative solution for patients seeking improved vision across a range of distances. The results from this study will be critical in determining the lens's safety and efficacy, and ultimately its path to regulatory approval and commercialization.
For more information about the company and its technology, interested parties can visit the original press release on NewMediaWire.
